Showing results (531-540 of 3,952) with videos related to

Sort By:
Pageof 396
Journal of Thoracic Disease|July 14, 2026
Prediction of one-year post-discharge mortality in patients with acute exacerbation of chronic obstructive pulmonary disease based on clinical characteristics, blood gas indicators, and duration of non-invasive ventilationLi-Na Huang, Xiao-Hong Zhu, Jin-Mei He
Alzheimer Disease and Associated Disorders|April 11, 2017
The BIOCARD Index: A Summary Measure to Predict Onset of Mild Cognitive ImpairmentNed Sacktor, Anja Soldan, Maura Grega, et al.
JAMA Neurology|April 12, 2016
Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive ChangeAnja Soldan, Corinne Pettigrew, Qing Cai, et al.
JAMA|February 13, 2014
Risk of end-stage renal disease following live kidney donationAbimereki D Muzaale, Allan B Massie, Mei-Cheng Wang, et al.
Archives of Pediatrics & Adolescent Medicine|January 12, 2002
Effects of improved access to safety counseling, products, and home visits on parents' safety practices: results of a randomized trialAndrea Carlson Gielen, Eileen M McDonald, Modena E H Wilson, et al.
Brain Imaging and Behavior|October 23, 2021
Computerized paired associate learning performance and imaging biomarkers in older adults without dementiaCorinne Pettigrew, Anja Soldan, Rostislav Brichko, et al.
Brain : a Journal of Neurology|January 25, 2018
Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 yearsMarilyn Albert, Yuxin Zhu, Abhay Moghekar, et al.
Pediatrics|February 5, 2008
Improving child and parent mental health in primary care: a cluster-randomized trial of communication skills trainingLawrence Sagin Wissow, Anne Gadomski, Debra Roter, et al.
Environment International|January 7, 2022
A metabolome-wide association study of in utero metal and trace element exposures with cord blood metabolome profile: Findings from the Boston Birth CohortMingyu Zhang, Jessie P Buckley, Liming Liang, et al.
Gynecologic Oncology|July 5, 2022
Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysisKun Liu, Youwen Zhu, Yangying Zhou, et al.
Pageof 396